Written and medically reviewed by Yuichi Wakabayashi, MD, PhD · American Board of Regenerative Medicine (ABRM) Board Certified · 15 MHLW-notified regenerative medicine treatment plans · Updated 2026-11-16
Osteoarthritis (OA) is a degenerative “wear-and-tear” disease of one or a few joints, while rheumatoid arthritis (RA) is a systemic autoimmune disease in which the immune system attacks the joint lining symmetrically across the body. This guide compares their causes, symptoms, hand and X-ray patterns, diagnosis, and treatment — including where regenerative medicine fits for joint damage in Japan. Here is what matters most:
- The key difference: the cause — osteoarthritis is mechanical joint damage from cartilage wearing down over time, while rheumatoid arthritis is an autoimmune disease in which the immune system mistakenly attacks the joints — meaning RA is systemic, often symmetric, and can affect the whole body.
- What the trials show: in a Phase III trial of 261 patients with KL grade 3 knee OA, a single injection of autologous ADSCs improved pain (100-mm VAS) by 25.2 vs 15.5 mm and WOMAC by 21.7 vs 14.3 points versus placebo at 6 months , with no serious treatment-related adverse events (Kim 2023); a 2025 meta-analysis of 8 RCTs (502 patients) found better WOMAC scores at 6 and 12 months than control (Cao 2025).
- Who it is mainly for: OA joints — and RA patients whose disease is under control but one knee or hip still hurts because the cartilage is already worn : that joint is now an osteoarthritis problem, and that is the kind of problem we assess. The autoimmune process of RA itself is not something we treat.
- Please note: Cell Grand Clinic does not hold a treatment plan filed specifically for rheumatoid arthritis; conditions that accompany it may fall within our MHLW-notified plans for knee osteoarthritis (Plan No. PB5260009) and chronic pain (Plan No. PB5240089).
- Who we are: Cell Grand Clinic in Osaka, Japan, led by Dr. Yuichi Wakabayashi, an American Board of Regenerative Medicine (ABRM) board-certified physician with more than 3,000 stem cell treatments. The clinic has 15 MHLW-notified regenerative medicine treatment plans.
- Our protocol: 100 million of your own cultured adipose-derived stem cells per session, given by injection into the damaged joint , after about 7 weeks of culture from a small sample of your own fat. No donor cells.
- Cost: from JPY 2,970,000 (approx. USD 19,800) per session for 100 million cells, tax included . Self-paid (not covered by public health insurance). Two visits to Osaka of about 3 days each.
- What’s the Difference Between Osteoarthritis and Rheumatoid Arthritis?
- Same Joint Pain, Two Very Different Diseases
- Is Osteoarthritis an Autoimmune Disease? (And Why RA Is)
- Symptoms Compared: How to Tell Them Apart
- Diagnosed With OA or RA? What to Do Next
- In the Hands: Which Joints Each Affects
- Diagnosis: Blood Tests and X-ray Differences
- Can You Have Both? Can One Turn Into the Other?
- Which Is Worse — Osteoarthritis or Rheumatoid Arthritis?
- Treatment Options: Can Arthritis Be Reversed?
- Regenerative Medicine in Japan: Stem Cell Therapy for OA and RA
- Take the Next Step
- Frequently Asked Questions
- References
What’s the Difference Between Osteoarthritis and Rheumatoid Arthritis?
The core difference between osteoarthritis and rheumatoid arthritis is the cause: osteoarthritis is mechanical joint damage from cartilage wearing down over time, while rheumatoid arthritis is an autoimmune disease in which the immune system mistakenly attacks the joints — meaning RA is systemic, often symmetric, and can affect the whole body.
That single distinction drives almost everything else — which joints are affected, how the pain behaves through the day, what shows up on blood tests and X-rays, and how each is treated. Here’s the practical breakdown most patients are actually looking for.

Same Joint Pain, Two Very Different Diseases
Both conditions cause joint pain and stiffness, but osteoarthritis affects roughly an order of magnitude more people than rheumatoid arthritis — and the two follow completely different paths, which is why an accurate diagnosis matters so much.
Why getting it right matters: rheumatoid arthritis can be slowed dramatically if it’s caught early and treated — so distinguishing it from ordinary wear-and-tear osteoarthritis is not just academic, it changes outcomes.
Is Osteoarthritis an Autoimmune Disease? (And Why RA Is)
No — osteoarthritis is not an autoimmune disease. It is a degenerative joint disease driven by mechanical wear, aging, and load on the cartilage. Rheumatoid arthritis, by contrast, is a systemic autoimmune disease: the immune system produces antibodies that attack the synovium (joint lining), causing body-wide inflammation.
This is the root reason the two behave so differently. Because RA is immune-driven, it tends to strike both sides of the body symmetrically and can also affect organs beyond the joints. Because OA is mechanical, it usually starts in the specific joints that have taken the most load over a lifetime — knees, hips, hands, and spine.
Symptoms Compared: How to Tell Them Apart
The fastest way to tell osteoarthritis from rheumatoid arthritis is the pattern of stiffness: OA stiffness is brief (under ~30 minutes) and worsens with use, while RA stiffness lasts longer (often over an hour each morning) and comes with systemic symptoms like fatigue and low-grade fever.
| Feature | Osteoarthritis (OA) | Rheumatoid Arthritis (RA) |
|---|---|---|
| Cause | Mechanical wear of cartilage | Autoimmune attack on joint lining |
| How common | 240M+ people worldwide | 17.6M people worldwide (2020) |
| Onset age | Usually 50+ | Any age, often 30–60 |
| Joints | One or a few, load-bearing: knees, hips, spine, base of thumb | Many: knuckles (MCP), middle finger joints (PIP), wrists, feet |
| Pattern | Often one-sided / asymmetric | Symmetric (both sides) |
| In the hands | End finger joints (DIP), bony nodes | Knuckles and middle joints, soft warm swelling, both hands |
| Morning stiffness | Brief (under ~30 min) | Prolonged (often over 1 hour) |
| Pain with activity | Worse with use, better with rest | Better with movement, worse after rest |
| Whole-body symptoms | None | Fatigue, low fever, malaise |
| Blood tests | Usually normal | RF, anti-CCP, CRP/ESR often raised |
| X-ray | Joint-space narrowing, bone spurs | Erosions at joint margins |
| Standard treatment | Exercise, weight management, NSAIDs, steroid injections; joint replacement when advanced | DMARDs, biologics, JAK inhibitors; early treat-to-target |
| Where regenerative medicine fits | The damaged joint itself (most trial evidence in the knee) | Not for the autoimmune disease; possibly for the joint it has damaged |
Download or print this chart (PDF) →
If your stiffness eases within a few minutes of moving and stays in one or two joints, it points toward OA. If both hands are stiff for an hour every morning and you feel run-down, that pattern points toward RA and is worth an urgent rheumatology check.
Diagnosed With OA or RA? What to Do Next
If you have osteoarthritis, the next step is a plan to protect the joint you have: exercise, weight management and, when injections stop working, non-surgical options that target the damaged joint. If you have rheumatoid arthritis, start disease-modifying treatment with a rheumatologist as early as possible; anything else is in addition to it, never instead of it.
The comparison above tells you which disease you probably have. It does not tell you what to do on Monday morning. Here is how the next step differs.
If it looks like osteoarthritis
Osteoarthritis is a problem of the joint, so the plan is about the joint: keep it moving, reduce the load on it, and treat the pain. Guidelines put exercise, weight loss where appropriate and education first, with NSAIDs and short-term steroid injections as add-ons (Katz 2021). The question most patients eventually ask is what to do when the injections stop working and surgery is all that is left on the table. That is where regenerative options sit: injections of your own cultured stem cells into the joint have been tested in randomized trials — a 2025 meta-analysis of 8 RCTs (502 patients) found better WOMAC scores at 6 and 12 months than control, with adipose-derived cells and higher doses doing better in subgroup analysis, and no difference in adverse events (Cao 2025). At our clinic the knee is the joint we treat most often; a single published case — a 67-year-old woman with KL grade 3 knee OA whose hyaluronic acid and PRP injections had stopped helping — went from pain 8/10 to 0/10 and a JOA knee score of 55 to 95 over 13 months after one injection of 100 million autologous cells (Wakabayashi 2026, Cureus). That is one patient, not a promise; results vary and some patients do not respond.
Alternatives to Knee Replacement: What Works at Each KL Grade, Including Bone-on-BoneCortisone and hyaluronic acid stopped working? The options between injections and a knee replacement. Read the knee options guide → Stem Cell Therapy for Knees: Does It Work, What to Expect, and What It CostsTrial results by KL grade, who qualifies, and the full cost of stem cell therapy for knee osteoarthritis. See results and cost →If it looks like rheumatoid arthritis
Rheumatoid arthritis is a disease of the immune system, so the plan is about the immune system: see a rheumatologist, confirm the diagnosis with anti-CCP, rheumatoid factor and inflammatory markers, and start a disease-modifying drug (DMARD) early — the first months matter most, and an increasing number of patients now reach remission (Di Matteo 2023). Stem cells do not change this. In trials, mesenchymal stem cells have been generally well tolerated in small trials, although serious adverse events have been reported, and they have produced modest improvements in disease activity; the effect tends to fade after a single infusion (in a 9-patient study of donor cord-blood cells, Park 2026), and no trial has shown they can replace medication (Álvaro-Gracia 2017).
What RA often leaves behind, even when it is well controlled, is a joint that has already been damaged — secondary osteoarthritis, with pain that your DMARD no longer touches. If your RA is under control but one knee or hip still hurts because the cartilage is already worn, that joint is now an osteoarthritis problem — and that is the kind of problem we assess.
Cell Grand Clinic does not hold a treatment plan filed specifically for rheumatoid arthritis. Conditions that accompany it — such as secondary osteoarthritis and chronic joint pain in joints RA has already damaged — may fall within our MHLW-notified plans for knee osteoarthritis (Plan No. PB5260009) and chronic pain (Plan No. PB5240089). Whether you are a candidate is decided by Dr. Wakabayashi after reviewing your symptoms and test results during the online consultation.
Stem Cell Therapy for Back & Neck Pain: Disc, Stenosis & After SurgeryWhat the evidence shows for chronic back and neck pain, why we use IV infusion rather than disc injection, and who may qualify. Read the back & neck pain guide →If you are not sure which you have
Get the blood tests and an X-ray. A normal rheumatoid factor and anti-CCP with joint-space narrowing on X-ray usually points to OA; positive antibodies with erosions usually point to RA. Some RA is seronegative, so a rheumatologist’s assessment still matters — and some people have both. If you already have blood results or an X-ray, bring them to the online consultation; the box below explains what it covers and what it costs.
Already have your X-ray or blood results — or not sure which arthritis you have?
Email or WhatsApp us about your condition. Dr. Wakabayashi replies personally and tells you whether stem cell therapy may be an option for you. Inquiries are free of charge. For a detailed review of your MRI or test results and a treatment plan, he offers a 60-minute online consultation (JPY 55,000, credited toward treatment). Treatment pricing from JPY 2,970,000 (approx. USD 19,800) per session, 100 million cells, tax included.
In the Hands: Which Joints Each Affects
In the hands, osteoarthritis typically affects the joints closest to the fingertips (DIP) and the base of the thumb, while rheumatoid arthritis typically affects the knuckles (MCP) and middle finger joints (PIP) — symmetrically on both hands.
This hand pattern is one of the most reliable visual clues. OA tends to produce bony, knobby enlargements at the end finger joints (Heberden’s nodes). RA tends to produce soft, warm, swollen knuckles on both hands at once, and over time can cause the characteristic finger drift seen in advanced disease.

Diagnosis: Blood Tests and X-ray Differences
The decisive difference at diagnosis is that rheumatoid arthritis shows up in blood tests (rheumatoid factor, anti-CCP antibodies, elevated CRP/ESR) and produces joint erosions on imaging, while osteoarthritis has no defining blood marker and shows joint-space narrowing and bone spurs on X-ray.
Doctors combine three things: your symptom pattern, blood work, and imaging. In OA, blood tests are typically normal and X-rays show narrowed joint space, osteophytes (bone spurs), and hardened bone. In RA, antibodies and inflammatory markers are often elevated, and imaging shows inflammatory erosions at the joint margins.

Can You Have Both? Can One Turn Into the Other?
Yes, you can have both osteoarthritis and rheumatoid arthritis at the same time — this is common in older adults — but one does not turn into the other, because they have completely different mechanisms.
Osteoarthritis will not “become” rheumatoid arthritis: wear-and-tear damage cannot transform into an autoimmune disease. However, people with long-standing RA often develop secondary OA in joints that have already been damaged by inflammation, so both can genuinely coexist in the same person — and even in the same joint.
Which Is Worse — Osteoarthritis or Rheumatoid Arthritis?
Neither is simply “worse” — they’re serious in different ways: rheumatoid arthritis is potentially more dangerous because it is systemic and can damage organs and shorten life expectancy if untreated, while osteoarthritis is usually localized but is the leading cause of joint disability worldwide.
Untreated RA can affect the heart, lungs, eyes, and blood vessels, which is why early immune-modulating treatment is so important. OA rarely threatens other organs, but advanced OA can be profoundly disabling and is the most common reason for hip and knee replacement. Both deserve proper diagnosis and a treatment plan.
Treatment Options: Can Arthritis Be Reversed?
Conventional treatment cannot fully reverse either disease — OA care focuses on managing pain and preserving function, and RA care focuses on suppressing the immune attack with disease-modifying drugs — but regenerative medicine aims at the joint damage itself, which is a different approach.
For osteoarthritis, where the problem is worn cartilage, mesenchymal stem cell (MSC) therapy is being used to reduce pain and support joint function, and the knee is where most randomized trials have been done: in a Phase III trial of 261 patients with KL grade 3 knee OA, a single injection of autologous ADSCs improved pain (100-mm VAS) by 25.2 vs 15.5 mm and WOMAC by 21.7 vs 14.3 points versus placebo at 6 months, with no serious treatment-related adverse events (Kim 2023). For rheumatoid arthritis, the rationale is different: stem cells have natural immunomodulatory properties, and early-stage trials are studying whether they can calm the autoimmune process. The honest summary of that evidence: generally well tolerated in small trials, although serious adverse events have been reported; improvement is modest and tends to fade after a single infusion; and no study has shown stem cells can replace DMARDs or biologics (Álvaro-Gracia 2017; Park 2026). For how this applies to joints RA has already damaged, see “What to do next” above.

Regenerative Medicine in Japan: Stem Cell Therapy for OA and RA
In Japan, stem cell therapy for arthritis uses a patient’s own adipose-derived stem cells (ADSCs) under MHLW oversight, with randomized-trial evidence in osteoarthritis of the knee and an early, still-investigated role in rheumatoid arthritis.
At Cell Grand Clinic, every treatment uses Grand Stem Cells — cultured exclusively for one patient, never pooled or off-the-shelf. Four standards define them: cells are cultured exclusively for you from your own fat tissue over seven weeks; each batch undergoes ISCT-standard verification to confirm genuine mesenchymal stem cells; cell viability is about 98% at release; and culture is limited to passage 3 or below to preserve cell quality, from 100 million cells per session. Every patient receives a Certificate of Quality documenting all four.

The table below sets out what to check in any stem cell clinic, and the corresponding facts for Cell Grand Clinic.
| What to check in any stem cell clinic | At Cell Grand Clinic |
|---|---|
| Regulatory basis | 15 regenerative medicine treatment plans notified to Japan’s MHLW under the Act on the Safety of Regenerative Medicine |
| Cell source | Your own adipose tissue (autologous); no donor cells, no pooled batches |
| Dose and culture | 100 million cells per session; about 7 weeks; passage 3 or below |
| Quality release | ISCT marker verification; viability about 98%; a Certificate of Quality per patient |
| Who reviews your case | Yuichi Wakabayashi, MD, PhD — NIH-trained, American Board of Regenerative Medicine (ABRM) Board Certified, 3,000+ treatments |
| Published outcome | A single peer-reviewed knee OA case report with 13-month follow-up (Cureus 2026) |
Main risks and side effects. Fat harvesting can cause swelling, bruising, infection, or a small scar at the harvest site. Cell administration can cause pain at the injection site and, temporarily, fever, fatigue, or difficulty sleeping. Intra-articular injection can cause temporary pain in the joint. Intravenous infusion is limited to a maximum of 200 million cells per session to avoid the risk of embolism, and a physician monitors you during the infusion. Results vary between individuals, and some patients do not respond. This is a self-paid treatment using an unapproved regenerative medicine product, and it is not covered by Japan’s Relief System for Sufferers from Adverse Drug Reactions.
Take the Next Step
You don’t have to live with joint pain indefinitely — and you don’t need to commit to anything to find out whether stem cell therapy could help your specific case.
When you reach out, here’s what happens:
- Within 1 business day: we confirm whether an online consultation is the right next step and how to book it
- Online consultation (JPY 55,000 per person, 60 min, credited toward treatment): Dr. Yuichi Wakabayashi, MD, PhD — American Board of Regenerative Medicine (ABRM) Board Certified — reviews your imaging and test results and tells you whether you are a candidate
- You receive the treatment plan and price in writing
- You decide — no obligation
Most international patients use this consultation simply to understand their options.
Available in English, Japanese, and Mandarin Chinese · Response within 1 business day, Japan time
Frequently Asked Questions
Is osteoarthritis the same as rheumatoid arthritis?
No. Osteoarthritis is a degenerative “wear-and-tear” disease of specific joints; rheumatoid arthritis is a systemic autoimmune disease that attacks the joints symmetrically and can affect the whole body.
Which is worse, osteoarthritis or rheumatoid arthritis?
They’re serious differently. RA can be more dangerous because it’s systemic and can harm organs if untreated; OA is usually localized but is the leading cause of joint disability and joint replacement.
Can you have both osteoarthritis and rheumatoid arthritis?
Yes. Both can occur in the same person — and even the same joint — especially in older adults, because RA-damaged joints often develop secondary OA.
Can osteoarthritis turn into rheumatoid arthritis?
No. They have different mechanisms, so OA cannot become RA. A person can develop both separately, but one does not convert into the other.
Can arthritis be reversed?
No treatment reverses either disease. Osteoarthritis care manages pain and protects function; rheumatoid arthritis care suppresses the immune attack. Regenerative medicine targets the damaged joint: in knee OA, a Phase III trial of autologous adipose-derived stem cells improved pain and function versus placebo at 6 months (Kim 2023). In RA the evidence is early and does not replace medication.
How do doctors tell osteoarthritis and rheumatoid arthritis apart?
By combining symptom pattern, blood tests (rheumatoid factor, anti-CCP, CRP/ESR), and imaging. RA shows antibodies and erosions; OA shows normal blood work with joint-space narrowing and bone spurs.
Can stem cell therapy treat rheumatoid arthritis?
Not as a replacement for RA medication. Trials show mesenchymal stem cells are generally well tolerated and may modestly reduce disease activity, but the effect faded after one infusion in a 9-patient study of donor cord-blood cells (Park 2026). Cell Grand Clinic does not treat RA itself; joint damage left by RA may fall within our MHLW-notified plans for knee osteoarthritis (Plan No. PB5260009) and chronic pain (Plan No. PB5240089), decided by Dr. Wakabayashi during the online consultation.
What should I do first after an osteoarthritis diagnosis?
Start with exercise, weight management and pain control under your doctor, and ask which joint is affected and how advanced it is (KL grade). If injections stop working and you want to avoid or delay surgery, non-surgical regenerative options exist; see our knee guides for what the trials show and who qualifies.
Stem Cell Therapy Pricing — from JPY 2,970,000 (approx. USD 19,800) per session, 100 million cells, tax included
The fee includes:
- 100 million autologous ADSCs for one session
- About 7 weeks of culture at a cell processing center licensed under Japan’s Act on the Safety of Regenerative Medicine
- Blood tests and fat harvest
- Cell quality certificate (viability about 98%, passage 3 or below, no batch pooling)
- Remote follow-up at 1, 3 and 6 months
Online consultation: JPY 55,000, credited toward treatment.
References
According to PubMed:
- Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019-2033. https://doi.org/10.1016/S0140-6736(23)01525-8
- Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591-602. https://doi.org/10.1038/s41584-022-00827-y
- Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568-578. https://doi.org/10.1001/jama.2020.22171
- Cao M, Ou Z, Sheng R, et al. Efficacy of mesenchymal stem cells for knee osteoarthritis: a meta-analysis. Stem Cell Res Ther. 2025;16(1):122. https://doi.org/10.1186/s13287-025-04252-2
- Kim KI, Lee MC, Lee JH, et al. Intra-articular injection of autologous adipose-derived stem cells for knee osteoarthritis: a Phase III trial. Am J Sports Med. 2023;51(9):2243-2253. https://doi.org/10.1177/03635465231179223
- Kim KI, Lee WS, Kim JH, et al. Five-year follow-up of autologous adipose-derived stem cell injection for knee osteoarthritis. Stem Cells Transl Med. 2022;11(6):586-596. https://doi.org/10.1093/stcltm/szac024
- Zeng L, Liu C, Wu Y, et al. Efficacy and safety of MSC transplantation in autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of RCTs. Stem Cell Res Ther. 2025;16(1):65. https://doi.org/10.1186/s13287-025-04184-x
- Mesa LE, López JG, López Quiceno L, et al. Safety and efficacy of mesenchymal stem cell therapy in rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2023;18(7):e0284828. https://doi.org/10.1371/journal.pone.0284828
- Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41(9):653-664. https://doi.org/10.1016/j.tips.2020.06.009
- Álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196-202. https://doi.org/10.1136/annrheumdis-2015-208918
- Park EH, Kim MJ, Kang KS, Shin K. Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study. Stem Cells Transl Med. 2026;15(8):szag062. https://doi.org/10.1093/stcltm/szag062
- GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594-e610. https://doi.org/10.1016/S2665-9913(23)00211-4
- Wakabayashi Y. Symptomatic improvement following intra-articular injection of cultured autologous adipose-derived mesenchymal stem cells in Kellgren-Lawrence grade 3 knee osteoarthritis: a case report with one-year follow-up. Cureus. 2026;18(8):e113830. https://doi.org/10.7759/cureus.113830
Updated: 2026.11.16
Inquiries by Email